Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$1.15
-0.4%
$1.22
$1.06
$5.50
$13.15M1.65254,044 shs59,797 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$14.44
+0.4%
$13.26
$8.88
$19.11
$1.22B1.721.16 million shs335,174 shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$6.14
+2.1%
$6.07
$3.75
$9.40
$27.67M1.5345,291 shs13,323 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.00%0.00%-7.26%-4.17%-64.83%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
+4.73%+11.65%+11.21%+10.19%+73.67%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-0.66%+1.01%+7.51%+17.15%+16.99%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$1.15
-0.4%
$1.22
$1.06
$5.50
$13.15M1.65254,044 shs59,797 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$14.44
+0.4%
$13.26
$8.88
$19.11
$1.22B1.721.16 million shs335,174 shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$6.14
+2.1%
$6.07
$3.75
$9.40
$27.67M1.5345,291 shs13,323 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.00%0.00%-7.26%-4.17%-64.83%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
+4.73%+11.65%+11.21%+10.19%+73.67%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-0.66%+1.01%+7.51%+17.15%+16.99%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
2.00
Hold$6.00424.02% Upside
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3.00
Buy$37.83162.06% Upside
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
2.00
Hold$6.00-2.20% Downside

Current Analyst Ratings Breakdown

Latest EYPT, HBIO, and BNGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Reiterated RatingBuy$68.00
5/7/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Lower Price TargetOutperform$39.00 ➝ $37.00
5/1/2026
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
UpgradeSell (E)Sell (E+)
4/21/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Reiterated RatingSell (D-)
4/13/2026
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
Lower Price TargetBuy$7.00 ➝ $6.00
3/27/2026
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Reiterated RatingSell (D-)
(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$28.51M0.46N/AN/A$4.37 per share0.26
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$7.61M158.97N/AN/A$3.70 per share3.90
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$86.55M0.32$11.80 per share0.52$3.07 per share2.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$26.40M-$4.37N/AN/AN/A-109.94%-71.38%-43.07%8/13/2026 (Estimated)
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$231.96M-$3.50N/AN/AN/A-3,566.63%-110.54%-90.15%8/5/2026 (Estimated)
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$56.70M-$2.17N/AN/AN/A-11.44%-25.78%-4.37%8/10/2026 (Estimated)

Latest EYPT, HBIO, and BNGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$0.88-$0.7610+$0.1190-$0.76$6.57 million$6.69 million
5/12/2026Q1 2026
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$0.62-$0.33+$0.29-$0.77$21.20 million$20.76 million
5/6/2026Q1 2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.79-$0.99-$0.20-$0.99$0.35 million$0.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.09
1.84
1.59
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
6.66
6.63
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
3.60
1.99
1.06

Institutional Ownership

CompanyInstitutional Ownership
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
11.35%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
80.87%

Insider Ownership

CompanyInsider Ownership
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.65%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
5.13%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
20.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
30011.48 million11.40 millionNo Data
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12083.84 million79.54 millionOptionable
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
4904.51 million3.59 millionOptionable

Recent News About These Companies

HBIO Q1 2026 Earnings Transcript
Harvard Bioscience: Q1 Earnings Snapshot
Harvard Bioscience, Inc. Q4 2025 Earnings Call Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bionano Genomics stock logo

Bionano Genomics NASDAQ:BNGO

$1.14 -0.01 (-0.43%)
As of 01:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$14.44 +0.06 (+0.40%)
As of 01:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Harvard Bioscience stock logo

Harvard Bioscience NASDAQ:HBIO

$6.14 +0.13 (+2.08%)
As of 01:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.